A
Andrea Law
Researcher at Clatterbridge Cancer Centre NHS Foundation Trust
Publications - 5
Citations - 7
Andrea Law is an academic researcher from Clatterbridge Cancer Centre NHS Foundation Trust. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 2 publications receiving 3 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Benjamin Hall,Ajay Ashok Bhojwani,Helen Wong,Andrea Law,Helen Flint,Eliyaz Ahmed,Helen Innes,Joanne Cliff,Zafar Malik,J. O'hagan,Allison Hall,Raj Sripadam,Shaun Tolan,Zulfiqar Ali,Clare Hart,Douglas Errington,Farida Alam,Rosa Giuliani,Shaveta Mehta,S. Khanduri,Nicky Thorp,Richard J. Jackson,Silvia Cicconi,Carlo Palmieri +23 more
TL;DR: In this article , the real-world efficacy and toxicity of neoadjuvant trastuzumab and pertuzumaab combined with chemotherapy for HER2-positive breast cancers (BC) have been investigated.
Journal ArticleDOI
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
Sam Wong,Kellati Prasad,Thomas K. Waddell,Natalie Charnley,Helen Wong,Andrea Law,Omi Parikh,Manon Pillai,Richard Griffiths,Shien Chow +9 more
TL;DR: Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor and has been shown to offer PFS and tolerance advantage compared to sorafenib among human studies.
Journal ArticleDOI
Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.
Benjamin Hall,Ajay Ashok Bhojwani,Helen Innes,Eliyaz Ahmed,Joanne Cliff,Zaf Malik,Julie O’Hagan,Shaun Tolan,Allison Hall,Khizar Hayat,Douglas Errington,Farida Alam,Nicky Thorp,Helen Flint,Andrea Law,Helen Wong,S O'Reilly,Richard J. Jackson,Silvia Cicconi,Carlo Palmieri +19 more
TL;DR: Neoadjuvant HER2 blockade with trastuzumab and pertuzumAB results in pathological complete response (pCR) rates of 39% to 62% and diarrhoea is reported in up to 73% of patients.
Journal ArticleDOI
Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
J Heseltine,Jennifer Allison,Sam Wong,K. Rajendra Prasad,Helen Wong,Z. Oong,Natalie Charnley,Andrea Law,Omi Parikh,Manon Pillai,T. Waddell,Richard Griffiths,Shien Chow +12 more
TL;DR: The real world experience of 1L T suggests comparable activity with randomized data and other TKIs, particularly in F and I IMDC risk groups, makes it an attractive option if unsuitable for combination therapies.
Journal ArticleDOI
Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis
J Heseltine,Jennifer Allison,Sam Wong,K. Rajendra Prasad,Z. Oong,Helen Wong,Andrea Law,Natalie Charnley,Omi Parikh,T. Waddell,Shien Chow +10 more